Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | Q9HBH1 | 1/20 | 0.31 | |
| ▸ | MMP2 | P08253 | 5/20 | 0.31 |
| ▸ | MMP3 | P08254 | 5/20 | 0.31 |
| ▸ | MMP1 | P03956 | 4/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769391 | 1.00 | CA2 (0.41) | CA2CTSCCYP1A2CYP3A4RECQL | |
| SCHEMBL2081935 | 1.00 | CA2 (0.41) | CA2CTSCCYP1A2CYP3A4RECQL | |
| Trifluoroacetic Acid SCHEMBL918802 | 0.91 | CA2 (0.37) | CA2CTSCMMP13 | |
| SCHEMBL7765975 | 0.83 | CTSC (0.32) | CTSCCYP1A2CYP3A4RECQLPDF | |
| SCHEMBL8374072 | 0.80 | CTSC (0.32) | CTSCPDF | |
| SCHEMBL27542499 | 0.80 | MMP2 (0.43) | CA2CYP3A4ALDH1A1MAPTMMP2 | |
| SCHEMBL27542496 | 0.80 | MMP2 (0.43) | CA2CYP3A4ALDH1A1MAPTMMP2 | |
| SCHEMBL2909005 | 0.79 | CA2 (0.38) | CA2ALDH1A1MMP2MMP3MMP1 | |
| SCHEMBL15623787 | 0.79 | FAAH (0.42) | CA2RECQLMAPK1ALDH1A1MMP13 | |
| SCHEMBL13449084 | 0.79 | HPGD (0.40) | CA2CYP1A2CYP3A4MAPTPDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896407-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| WO-2006137782-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | claimed |
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7842684-B2 | 2-azetidinone derivatives such as N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine, used for the treatment of hyperlipemia | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20090069285-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-2013165-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | Astra Zeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1896459-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007126358-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006137797-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1699758-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061451-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | CYP46A1, CYP51A1, NPC1L1 | CA2 2522/4885CTSC 135/4885CYP1A2 91/4885 |
| US-20090069285-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity | CYP46A1, NPC1L1, NPC1 | CA2 3419/4885CTSC 360/4885CYP1A2 55/4885 |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | CA2 1731/4885CTSC 347/4885CYP1A2 54/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | CA2 2644/4885CTSC 150/4885CYP1A2 82/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | CA2 2644/4885CTSC 150/4885CYP1A2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.